Skip to main content
Fig. 1 | BMC Urology

Fig. 1

From: A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands

Fig. 1

Patient selection flowchart. *Patients excluded by exclusion/inclusion criterion, applied independently from each other; ‡A continuous follow-up period was confirmed by the dispensation of any medication 6 months prior to the index date and 12 months following the index date, with no gap in pharmacy records; §Patients with more than two drugs prescribed within 30 days of each other. 5-ARI: 5α-reductase inhibitor; FDC: fixed-dose combination; LUTS/BPH: lower urinary tract symptoms associated with benign prostatic hyperplasia

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us